Inovio to commence Covid-19 vaccine prime-boost trials in China


Source: pharmaceutical-technology.com pharmaceutical-technology.com

Key Topics in this News Article:

News Snapshot:

[FDA approves Sanofi’s Nexviazyme for Pompe disease treatment] Inovio to commence Covid-19 vaccine prime-boost trials in China The trials, sponsored by Advaccine, will evaluate prime-boosting with Inovio’s INO-4800 and Sinovac’s CoronaVac in healthy adults. Inovio has obtained regulatory approval from China’s Center for Drug Evaluation of the National Medical Products Administration to conduct two clinical trials of heterologous prime-boosting with its Covid-19 vaccine candidate, INO-4800. INO-4800 contains a specifically designed deoxyribonucleic acid (DNA) plasmid. It can be injected intradermally with subsequent electroporation to carry the DNA plasmid directly into body cells. The company’s partner, Advaccine Biopharmaceuticals Suzhou, will sponsor the...